Bristol-Myers is surfing for first place on the $33B PD-1 tsunami: analysts

There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb ($BMY), Merck ($MRK), AstraZeneca ($AZN) and Roche ($RHHBY) are speeding ahead with their research in the field, with Sanofi ($SNY), Novartis ($NVS) and Pfizer ($PFE) racing to catch up.

But according to Morningstar, those sales estimates are low--way low.

In fact, according to a new report from the investment firm, the market for PD-1 and PD-L1 drugs is billions of dollars richer than many analysts believe. That's good news for every drugmaker in the field. But the best news from Morningstar comes for Bristol-Myers. More

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.